臺灣博碩士論文加值系統

目的：肝細胞癌是極為惡性之疾病，在台灣地區高居男性十大癌症死亡首位，佔女性癌症死亡第二位。歷年來肝細胞癌相關研究多著重於較好發的男性，鮮少進行女性肝細胞癌危險因子之探討，本研究係以世代研究探討肝炎病毒、抽菸、喝酒、肥胖、家族疾病史、及荷爾蒙相關因子，在女性肝細胞癌中所扮演的角色。

方法：本研究世代係參與『社區常見癌症篩檢研究計畫』(Community-Based Cancer Screening Project, CBCSP)的11920名女性個案，平均追蹤11.5年後，共有71名肝細胞癌新發個案，利用Cox 比例危險模式(Cox proportional hazards model)，針對不同病毒感染情況及可能危險因子進行單變項及多變項分析。

結果：經過人口學變項調整後，相較於B型肝炎非表面抗原帶原者，e抗原陰性與陽性的B型肝炎表面抗原帶原者，罹患肝細胞癌的相對危險性分別為2.8 (95%信賴區間：1.5-5.2) 及15.5 (95%信賴區間: 7.5-31.9)。若B型肝炎病毒DNA複製量在105 copies/mL以上，與無法測得HBV DNA之表面抗原帶原者相較，則有9倍罹患肝細胞癌的相對危險性 (95%信賴區間: 3.1-26.4)。經過多變項分析後，抽菸習慣、停經早於50歲、肥胖、及肝癌肝硬化家族史等，皆會增加女性肝細胞癌的危險性。在肝炎病毒共同感染分析中，單獨B型肝炎病毒慢性感染有16.2倍罹患肝細胞癌的相對危險性，單獨C型肝炎病毒慢性感染有18.6倍的相對危險性，而共同感染的相對危險性提高到30.2 (95%信賴區間: 8.7-105.0)。在次世代分析中，單獨B型肝炎病毒慢性感染有4.5倍罹患肝細胞癌的相對危險性，單獨人類乳突瘤病毒感染有1.3倍的相對危險性，而共同感染的相對危險性提高到14.1倍(95%信賴區間: 3.9-51.5)。

結論：在慢性肝炎病毒感染盛行的台灣，B型及C型肝炎病毒感染仍在女性肝細胞癌的發生上扮演重要的角色。抽煙、肥胖、較早停經等，也都會提高女性肝細胞癌的危險性。

Objective: Hepatocellular carcinoma (HCC) is a leading malignant neoplasm with an extraordinarily high fatality. It is the first leading cancer death in men and the second leading cancer death in women in Taiwan. Most previous cohort studies on HCC risk factor were focused on males. This long-term follow-up study on a large female cohort aimed to analyze HCC risk factors including virus infection, lifestyle factors, obesity, familial disease history, and reproductive factors.

Methods: From 1991 to 1992, we enrolled 11920 women with ages between 30 and 65 years from seven townships in Taiwan. Lifestyle and reproductive risk factors were collected at recruitment through a standardized personal interview based on a structured questionnaire. Blood samples collected at cohort entry were tested for HBsAg and HBeAg by radioimmunoassay, HBV DNA by polymerase chain reaction, anti-HCV by enzyme immunoassay, and HPV genotyping by genechip hybridization. The relationship of potential risk factors measured at study entry was analyzed using Cox proportional hazards model.

Results: There were 71 newly-diagnosed HCC cases during 136,575 person-years of follow-up. The HCC incidence rate was 52 per 100.000 person-years. The relative risk (RR) of developing HCC was 2.8 (95% confidence interval, CI: 1.5-5.2) among women who were only HBsAg seropositive, and 15.5 (95%CI: 7.5-31.9) among those who were seropositive for both HBsAg and HBeAg in comparison with those who were seronegative on HBsAg and HBeAg. The RR of developing HCC for a serum HBV DNA level >105 copies/mL was 9.0 (95%CI: 3.1-26.4). In the multivariate analysis, statistically significant HCC risk factors other than viral infection included cigarette smoking, early menopause (<50 years), obesity, and family history of liver cirrhosis and HCC. In the analysis of interaction between HBV and HCV chronic infection, there was no synergistic effect. In the subcohort analysis of association between HCC and HPV, the RR (95% CI) were 4.5 (1.7-11.8), 1.3 (0.3-5.7), 14.1 (3.9-51.5), respectively, for only HBsAg-seropositive, only HPV DNA positive, and both positive in comparison with those without both infections.

Conclusion: In Taiwan, an area endemic of chronic hepatitis virus infection, both HBV and HCV were playing a major role in the development of HCC. Cigarette smoking, early menopause and obesity were also important HCC risk factors.

目錄……………………………………………………………………Ⅰ
表目錄…………………………………………………………………Ⅲ
中文摘要………………………………………………………………Ⅳ
英文摘要………………………………………………………………Ⅵ

第一章 前言............................................1

第二章 文獻探討
第一節 肝細胞癌描述流行病學............................2
第二節 肝細胞癌危險因子................................4

第三章 材料與方法
第一節 研究目的.......................................15
第二節 研究設計.......................................15
第三節 研究世代.......................................16
第四節 資料收集.......................................17
第五節 B型肝炎表面抗原及e抗原、C型肝炎抗體、人類乳突瘤病 毒測定...................................................19
第六節 資料分析.......................................21

第四章 結果
第一節 基本人口學資料.................................22
第二節 HBV與危險因子之危險性分析......................24
第三節 病毒交互作用之分析.............................35
第四節 多變項調整模式.................................41

第五章 討論...........................................43

參考文獻...............................................52

1. 中華民國九十年癌症登記報告.
2. Lee DH, Choi BH, Rho HM. The synergistic transactivation of the hepatitis B viral (HBV) pregenomic promoter by the E6 protein of human papillomavirus type 16 (HPV-16 E6) with HBV X protein was mediated through the AP1 site of E element in the enhancer I (EnI) in human liver cell. Biochem Biophys Res Commun. 1999;265(1):62-6.
3. Scinicariello F, Sato T, Lee CS, Hsu HC, Chan TS, Tyring SK. Detection of human papillomavirus in primary hepatocellular carcinoma. Anticancer Res. 1992;12(3):763-6.
4. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12((9-10)):S294-308.
5. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol. 2002;32:Suppl:S66-81.
6. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745-50.
7. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19(1):3-23.
8. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev. 1997;6(6):387-400.
9. Lancaster WD. Viral role in cervical and liver cancer. Cancer 1992;70(6 Suppl):1794-8.
10. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2(7):395-403.
11. Francis V. Chisari. Viruses, Immunity, and Cancer: Lessons from Hepatitis B. American Journal of Pathology. 2000;156:1117-32.
12. Lu SN, Lin TM, Chen CJ, Chen JS, Liaw YF, Chang WY, et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer. 1988;62(9):2051-5.
13. Chen CJ, Liang KY, Chang AS, Chang YC, Lu SN, Liaw YF, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology. 1991;13(3):398-406.
14. Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res. 1991;51(20):5621-5.
15. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61(10):1942-56.
16. You SL, Yang HI, Chen CJ. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med. 2004;36(3):215-24.
17. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168-74.
18. Mahmood S, Niiyama G, Kamei A, Izumi A, Nakata K, Ikeda H, et al. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int. 2005;25(2):220-5.
19. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97(4):265-72.
20. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
21. Idilman R, De Maria N, Colantoni A, Van Thiel DH. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepat. 1998;5(5):285-99.
22. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35-46.
23. Kiyosawa K, Tanaka E. Characteristics of hepatocellular carcinoma in Japan. Oncology. 2002;62(Suppl 1):5-7.
24. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127(5 Suppl 1):S17-26.
25. Chuang WL, Chang WY, Lu SN, Su WP, Lin ZY, Chen SC, et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer. 1992;69(8):2052-4.
26. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res. 1993;53(4):790-4.
27. Chang CC, Yu MW, Lu CF, Yang CS, Chen CJ. A nested case-control study on association between hepatitis C virus antibodies and primary liver cancer in a cohort of 9,775 men in Taiwan. J Med Virol. 1994;43(3):276-80.
28. Kaklamani E, Trichopoulos D, Tzonou A, Zavitsanos X, Koumantaki Y, Hatzakis A, et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA. 1991;265(15):1974-6.
29. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75(3):347-54.
30. I. C. Hsu, R. A. Metcalf, T. Sun, J. A. Welsh, N. J. Wang, C. C. Harris. Mutational hot spot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427 - 28.
31. Brigitte Bressac, Michael Kew, Jack Wands, Mehmet Ozturk. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 1991;350:429 - 31.
32. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer. 1996;67(5):620-5.
33. Chen CJ, Yu MW, Liaw YF, Wang LW, Chiamprasert S, Matin F, et al. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am J Hum Genet. 1996;59(1):128-34.
34. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People''s Republic of China. Cancer Epidemiol Biomarkers Prev. 1994;3(1):3-10.
35. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer. 2000;89(1):53-9.
36. Oshima A, Tsukuma H, Hiyama T, Fujimoto I, Yamano H, Tanaka M. Follow-up study of HBs Ag-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer. 1984;34(6):775-9.
37. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155(4):323-31.
38. Wang LY, You SL, Lu SN, Ho HC, Wu MH, Sun CA, et al. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control. 2003;14(3):241-50.
39. Corrao G, Arico S, Zambon A, Torchio P, Di Orio F. Female sex and the risk of liver cirrhosis. Collaborative Groups for the Study of Liver Diseases in Italy. Scand J Gastroenterol. 1997;32(11):1174-80.
40. Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst. 2001;93(21):1644-51.
41. Yuan JM, Ross RK, Stanczyk FZ, Govindarajan S, Gao YT, Henderson BE, et al. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer. 1995;63(4):491-3.
42. Mucci LA, Kuper HE, Tamimi R, Lagiou P, Spanos E, Trichopoulos D. Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. BJOG. 2001;108(3):291-4.
43. La Vecchia C, Negri E, Franceschi S, D''Avanzo B. Reproductive factors and the risk of hepatocellular carcinoma in women. Int J Cancer. 1992;52(3):351-4.
44. Hsing AW, McLaughlin JK, Hoover RN, Co Chien HT, Blot WJ, Fraumeni JF Jr. Parity and primary liver cancer among young women. J Natl Cancer Inst. 1992;84(14):1118-9.
45. Yu MW, Chang HC, Chang SC, Liaw YF, Lin SM, Liu CJ, et al. Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology. 2003;38(6):1393-400.
46. The Collaborative MILTS Project Team. Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). Contraception. 1997;56(5):275-84.
47. Hannaford PC, Kay CR, Vessey MP, Painter R, Mant J. Combined oral contraceptives and liver disease. Contraception. 1997;55(3):145-51.
48. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer. 1993;67(3):635-7.
49. Sorensen HT, Friis S, Olsen JH, Thulstrup AM, Mellemkjaer L, Linet M, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998;28(4):921-5.
50. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37(3):520-7.
51. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145(11):1039-47.
52. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000;92(14):1159-64.
53. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36(1):150-5.
54. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38.
55. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35(6):1485-93.
56. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54(4):533-9.
57. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection.[see comment]. Hepatology 1999;29(2):328-33.
58. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88(20):1472-7.
59. Ferber MJ, Montoya DP, Yu C, Aderca I, McGee A, Thorland EC, et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene. 2003;22(24):3813-20.
60. Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis. 2003;24(7):1167-76.
61. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-27.
62. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025-9.
63. Stanford JL, Thomas DB. Reproductive factors in the etiology of hepatocellular carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Causes Control. 1992;3(1):37-42.
64. Tzonou A, Zavitsanos X, Hsieh CC, Trichopoulos D. Liveborn children and risk of hepatocellular carcinoma. Cancer Causes Control. 1992;3(2):171-4.
65. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J (Clin Res Ed). 1986;292(6532):1355-7.
66. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 1989;44(5):833-9.
67. Combined oral contraceptives and liver cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 1989;43(2):254-9.
68. La Vecchia C, Negri E, Franceschi S, D''Avanzo B. Contraceptive steroids as a risk factor for hepatocellular carcinoma: a case/control study in South African black women. Hepatology. 1990;11(2):298-302.
69. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer.: 1991;49(2):182-5.
70. De Maria N, Manno M, Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol. 2002;193(1-2):59-63.
71. Shimomura M, Higashi S, Mizumoto R. 32P-postlabeling analysis of DNA adducts in rats during estrogen-induced hepatocarcinogenesis and effect of tamoxifen on DNA adduct level. Jpn J Cancer Res. 1992;83(5):438-44.
72. Hurd C, Khattree N, Dinda S, Alban P, Moudgil VK. Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. Oncogene. 1997;15(8):991-5.
73. I. S. Impact of oestrogens on the progression of liver disease. Liver Int. 2003;23(1):63-9.
74. Lu SN, Chue PY, Chen HC, Wu MH, Chen IL, Huang JF, et al. Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol. 1997;12(7):547-50.
75. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis. 1990;162(4):817-22.
76. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003;157(8):674-82.
77. Dienes HP, Purcell RH, Popper H, Ponzetto A. The significance of infections with two types of viral hepatitis demonstrated by histologic features in chimpanzees. J Hepatol. 1990;10(1):77-84.
78. Lancaster WD. Viral role in cervical and liver cancer. Cancer. 1992;70(6 Suppl):1794-8.
79. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer. 2003;106(3):334-41.
80. Ding X, Park YN, Taltavull TC, Thung SN, Jin X, Jin Y, et al. Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries. Jpn J Infect Dis. 2003;56(1):12-8.
81. Doitsh G, Shaul Y. HBV transcription repression in response to genotoxic stress is p53-dependent and abrogated by pX. Oncogene. 1999;18(52):7506-13.
82. Ori A, Zauberman A, Doitsh G, Paran N, Oren M, Shaul Y. p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J. 1998;17(2):544-53.